within Pharmacolibrary.Drugs.ATC.N;

model N06AA21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.66,
    Cl             = 0.38333333333333336,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Maprotiline is a tetracyclic antidepressant, primarily used for the treatment of depressive disorders, especially major depressive disorder and associated anxiety. It inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin. Its use has declined in favor of newer antidepressants due to safety concerns, but it is still approved and used in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration, under fasting conditions.</p><h4>References</h4><ol><li><p>Hrdina, PD, et al., &amp; Morselli, PL (1980). Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. <i>Psychopharmacology</i> 70(1) 29–34. DOI:<a href=&quot;https://doi.org/10.1007/BF00432366&quot;>10.1007/BF00432366</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6775331/&quot;>https://pubmed.ncbi.nlm.nih.gov/6775331</a></p></li><li><p>Miyake, K, et al., &amp; Kimura, Y (1992). Pharmacokinetic analysis of maprotiline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of maprotiline. <i>Journal of pharmaceutical sciences</i> 81(10) 1032–1037. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600811016&quot;>10.1002/jps.2600811016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1432616/&quot;>https://pubmed.ncbi.nlm.nih.gov/1432616</a></p></li><li><p>Alkalay, D, et al., &amp; LeSher, A (1980). Bioavailability and kinetics of maprotiline. <i>Clinical pharmacology and therapeutics</i> 27(5) 697–703. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1980.99&quot;>10.1038/clpt.1980.99</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7371367/&quot;>https://pubmed.ncbi.nlm.nih.gov/7371367</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AA21;
